Your browser doesn't support javascript.
loading
Correction: Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2L914F mutation in endothelial cells.
Lazovic, Bojana; Nguyen, Hoang-Tuan; Ansarizadeh, Mohammadhassan; Wigge, Leif; Kohl, Franziska; Li, Songyuan; Carracedo, Miguel; Kettunen, Jere; Krimpenfort, Luc; Elgendy, Ramy; Richter, Kati; De Silva, Laknee; Bilican, Bilada; Singh, Prateek; Saxena, Pratik; Jakobsson, Lars; Hong, Xuechong; Eklund, Lauri; Hicks, Ryan.
Afiliação
  • Lazovic B; BioPharmaceuticals R&D Cell Therapy Department, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Nguyen HT; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Ansarizadeh M; Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
  • Wigge L; Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
  • Kohl F; Finnadvance Ltd., Oulu, Finland.
  • Li S; Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
  • Carracedo M; Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Kettunen J; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Krimpenfort L; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Elgendy R; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Richter K; Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • De Silva L; Finnadvance Ltd., Oulu, Finland.
  • Bilican B; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
  • Singh P; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Saxena P; Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
  • Jakobsson L; Oulu Center for Cell-Matrix Research, Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland.
  • Hong X; Translational Genomics, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Eklund L; Finnadvance Ltd., Oulu, Finland.
  • Hicks R; BioPharmaceuticals R&D Cell Therapy Department, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Angiogenesis ; 27(3): 543-544, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38922558
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Angiogenesis Assunto da revista: HEMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Angiogenesis Assunto da revista: HEMATOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia